Effect of HIV, antiretrovirals, and genetics on methadone pharmacokinetics: Results from the methadone antiretroviral pharmacokinetics study

Keyphrases

• Antiretroviral 100%
• ATP Binding Cassette Subfamily B Member 1 (ABCB1) 11%
• Covariate Modelling 5%
• Cytochrome P450 2D6 (CYP2D6) 5%
• Drug Effects 5%
• Drug Interactions 11%
• Efavirenz 33%
• First-order Conditional Estimation 5%
• HIV Antiretrovirals 100%
• HIV Genetics 100%
• HIV Infection 5%
• HIV Patients 5%
• HIV Status 5%
• Inter-individual Variability 5%
• Methadone 100%
• Methadone Dose 11%
• Methadone Treatment 5%
• Nevirapine 22%
• NR1I3 11%
• One-compartment 5%
• Opioid Use Disorder 5%
• Parameter Estimation 5%
• Pharmacokinetic Study 100%
• Pharmacokinetics 100%
• Population Pharmacokinetic Model 5%
• Population Pharmacokinetics 5%
• Single nucleotide Polymorphism 5%
• Vietnam 5%
• Volume of Distribution 5%

Neuroscience

• Blood Plasma 4%
• Body Mass Index 4%
• Cofactor 9%
• CYP2B6 4%
• Drug Interaction 9%
• Efavirenz 28%
• Human Immunodeficiency Virus 100%
• Methadone 100%
• Nevirapine 19%
• Pharmacokinetics 100%
• Single-Nucleotide Polymorphism 4%

Pharmacology, Toxicology and Pharmaceutical Science

• CYP2B6 5%
• Diseases 5%
• Drug-Drug Interaction 10%
• Efavirenz 30%
• HIV 100%
• Human Immunodeficiency Virus Infection 5%
• Methadone 100%
• Methadone Treatment 5%
• Nevirapine 20%
• Pharmacokinetics 100%
• Volume of Distribution 5%